Request Demo
Last update 16 Sep 2026
LPM526000133
Last update 16 Sep 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LPM526000133富马酸盐, LPM526000133, LY03017 |
Action inverse agonists, antagonists |
Mechanism 5-HT2A receptor inverse agonists(Serotonin 2a (5-HT2a) receptor inverse agonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with LPM526000133CTR20254972
评价LPM526000133富马酸盐胶囊治疗阿尔茨海默病精神病性障碍（ADP）相关幻觉和妄想的初步疗效和安全性的随机、双盲、平行、安慰剂对照、IIa期临床研究
[Translation] A randomized, double-blind, parallel, placebo-controlled, phase IIa clinical study evaluating the preliminary efficacy and safety of LPM526000133 fumarate capsules in the treatment of hallucinations and delusions associated with Alzheimer's disease psychotic disorders (ADP).
NCT06980207
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
NCT06793995
A Phase 1 Study to Evaluate the Effect of Food and Age on the Pharmacokinetics of LPM526000133 Fumarate Capsules (LY03017) in Healthy Volunteers
100 Clinical Results associated with LPM526000133
Login to view more data
100 Translational Medicine associated with LPM526000133
Login to view more data
100 Patents (Medical) associated with LPM526000133
Login to view more data
100 Deals associated with LPM526000133
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Delusions | Phase 2 | China | 05 Mar 2026 | |
| Hallucinations | Phase 2 | China | 05 Mar 2026 | |
| Alzheimer Disease | Phase 1 | China | 10 May 2024 | |
| Parkinson Disease | Phase 1 | China | 10 May 2024 | |
| Schizophrenia | Phase 1 | China | 10 May 2024 | |
| Depressive Disorder | IND Approval | China | 20 Aug 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free